Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CBL mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
CBL mutation	Chronic Myelomonocytic Leukemia	CBL mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
CBL mutation	Sarcoma	CBL mutation	Sarcoma	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation	Non Small Cell Lung Cancer	CBL mutation	Non Small Cell Lung Cancer	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation	Melanoma	CBL mutation	Melanoma	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation	Non Small Cell Lung Cancer	CBL mutation	Non Small Cell Lung Cancer	SU11274 Sensitive: D – Preclinical SU11274 Sensitive : D	SU11274 Sensitive: D – Preclinical SU11274 Sensitive : D
CBL mutation	Chronic Myelomonocytic Leukemia	CBL mutation	Chronic Myelomonocytic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D